Rajesh Dash
Cardiovascular Disease · Stanford, CANPI 1205051018
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Novartis accounts for 64.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $3,611 and has fallen 82.7% since, to $624 in 2025.
Across 50 payments — averaging $146.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5K
- Bayer$1K
- Intuitive Surgical$411
- Heartflow, Inc.$343
- Amgen$270
- Esperion Therapeutics, Inc.$172
- plus $183 from 2 others
Across 11 payments — averaging $266,373 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.7M
- GE HealthCare$199K
- Cleerly, Inc.$42
What the payments were for
- Consulting fees$2,40033%
- Travel & lodging$1,39919%
- Food & beverage$3,12743%
- Education$4116%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 31 | $4,700 |
| Bayer | 9 | $1,258 |
| Intuitive Surgical | 1 | $411 |
| Heartflow, Inc. | 1 | $343 |
| Amgen | 4 | $270 |
| Esperion Therapeutics, Inc. | 2 | $172 |
| Cleerly, Inc. | 1 | $156 |
| Chiesi USA, Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LEQVIO$1,359
- Da Vinci Surgical System$411
- FFRct$343
- ENTRESTO$234
- Cleerly Ischemia$156
- Cleerly Labs$156
- NEXLETOL$139
How this compares
$7,337 in reported general payments places this provider in the 70th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $18,718 |
| Ezetimibe | 17 | $1,028 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 45 | $672 |
| Rosuvastatin Calcium | 36 | $658 |
| Metoprolol Succinate | 38 | $446 |
| Amlodipine Besylate | 36 | $283 |
| Atorvastatin Calcium | 26 | $279 |
| Lisinopril | 29 | $218 |
| Nitroglycerin | 12 | $195 |
| Simvastatin | 17 | $194 |
| Furosemide | 18 | $184 |
| ClopidogrelClopidogrel Bisulfate | 15 | $163 |
| Carvedilol | 18 | $155 |
| Losartan Potassium | 19 | $35 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Stanford
- Wilber SuStanford$1.1M
- Euan AshleyStanford$508K
- Kenneth MahaffeyStanford$447K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.